The name Anuncia comes from uncia uncia, the species name of the snow leopard. Called by the World Wildlife Foundation as “Guardians of the Headwaters,” they roam the headwater areas of the western basins, including the Indus, Amu Darya, and Syr Darya in Asia.
This website is dedicated to information for the hydrocephalus community on new technologies and solutions aimed towards improving patients’ lives and providing clinicians innovative technologies to treat hydrocephalus.
The Anuncia team consists of scientists, clinicians, engineers, patients, and professionals with a depth of expertise in hydrocephalus and medical technology innovation. Our singular focus is to develop an innovative therapeutic platform of products to address the unmet clinical need in hydrocephalus treatment.
LOWELL, Mass., Feb. 20, 2018 — AlcyoneLifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company… Read More
LOWELL, Mass., Nov. 15, 2017 — Alcyone Lifesciences, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the Alivio Ventricular Catheter & Flusher System (Alivio System) for the treatment of hydrocephalus. This comes on the heels of Alcyone receiving the EU CE Mark last month. The FDA 510(k) clearance and EU approval permit Alcyone Lifesciences to commercialize the Alivio System in the US, and Europe, to provide qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter, to unblock occluded inlet holes or open a relief membrane to restore or increase cerebrospinal fluid (CSF) flow in a non-flowing shunt…. Read More
LOWELL, Mass., Oct. 24, 2017 — Alcyone Lifesciences, Inc., a leader in advanced precision delivery for neurological conditions, and innovator in the treatment of hydrocephalus, announced receipt of CE (Conformité Européenne) Mark approval for European commercialization of its Alivio Ventricular Catheter and Flusher System for the treatment of Hydrocephalus… Read More
LOWELL, Mass., Aug. 2, 2016 — Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and an innovator in the treatment of hydrocephalus, announced the clinical use of its ReFlow™ System in four patients treated to date in an institutional review board (IRB)-approved study at Boston Children’s Hospital… Read More
“Alcyone has Spun-off Anuncia Inc, a patient-centric company solely focused on the treatment of Hydrocephalus, with ReFlow™ as its first product. [www.ReFlowVentCath.com]”